{"disease":{"id":"therapy-related-acute-myeloid-leukemia","name":"therapy related acute myeloid leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01420926","title":"Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02397720","title":"Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03894852","title":"SRSF2 Gene Mutation in Patients With t-MDS/AML","phase":"","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"Zeinab Albadry Mohammed Zahran","has_results":false},{"nct_id":"NCT06143839","title":"VYxeoS Liposomal Italian Observational Study iN the Real Practice","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT04128501","title":"Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03226418","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT01823198","title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01760655","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT01238211","title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01253070","title":"Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01904136","title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03330821","title":"Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03526926","title":"A Post-Marketing Observational Study of VYXEOS™","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT04062266","title":"AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01640301","title":"Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03009240","title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04269213","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT01130506","title":"Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02323607","title":"Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Bhavana Bhatnagar","has_results":false},{"nct_id":"NCT02438761","title":"PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT04518345","title":"TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Uma Borate","has_results":false},{"nct_id":"NCT03272633","title":"Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03602898","title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}